Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1999-12-08
2001-07-17
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S315100
Reexamination Certificate
active
06262102
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to a pharmaceutically active compound, compositions containing the compound and methods of using the compound in the treatment of certain disease states in mammals, in particular man. More specifically, the present invention relates to (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate, compositions containing this compound, and methods of using (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate monohydrate to block angiotensin II (AII) receptors and to treat hypertension, congestive heart failure and renal failure.
BACKGROUND OF THE INVENTION
The compound (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is known by the name “eprosartan” and is the subject of U.S. Pat. No. 5,185,351 (the '351 patent), issued Feb. 9, 1993. This patent discloses in Example 41 a process for making the anhydrous form of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate. Additionally, the '351 patent discloses conventional techniques for formulating (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate and Example; 108-111 specifically detail the preparation of certain formulations. This compound is claimed to have utility in blocking angiotensin II receptors and to be useful in the treatment of hypertension, congestive heart failure and renal failure.
It has been found that the monohydrate of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is formed during the vacuum drying of the dihydrated form of this compound or when the anhydrate of (E)-&agr;-[2-n-butyl-1-[(4-carboxy-phenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate is granulated with water, stored at 50° C. overnight and vacuum dried overnight at ambient temperature.
SUMMARY OF THE INVENTION
The present invention provides a novel monohydrate of (E)-&agr;-[2-n-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene-2-thiophenepropionic acid monomethanesulfonate, in particular, in pharmaceutical compositions for the treatment of diseases in which blockade of angiotensin II receptors is indicated, for example, in the treatment of hypertension, congestive heart failure and renal failure.
REFERENCES:
patent: 5185351 (1993-02-01), Finkelstein et al.
Sheng, Jie et al, J. Pharm. Sci., 88, 1999, 1021-1029.
Duddu Sarma
Palepu Nageswara R
Venkatesh Gopadi M
Kinzig Charles M.
McCarthy Mary E.
McKenzie Thomas
Shah Mukund J.
SmithKline Beecham Corporation
LandOfFree
Eprosartan monohydrate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Eprosartan monohydrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eprosartan monohydrate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2515376